Literature DB >> 22736787

Inconvenience of convenience cohorts--letter.

Daniel Williamson, Edoardo Missiaglia, Julia Chisholm, Janet Shipley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22736787      PMCID： PMC3428849          DOI： 10.1158/1055-9965.EPI-12-0724

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN： 1055-9965            Impact factor:   4.254


× No keyword cloud information.
  5 in total

1.  Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.

Authors:  Daniel Williamson; Edoardo Missiaglia; Aurélien de Reyniès; Gaëlle Pierron; Benedicte Thuille; Gilles Palenzuela; Khin Thway; Daniel Orbach; Marick Laé; Paul Fréneaux; Kathy Pritchard-Jones; Odile Oberlin; Janet Shipley; Olivier Delattre
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

2.  Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group.

Authors:  Frederic G Barr; Lynette M Smith; James C Lynch; Donna Strzelecki; David M Parham; Stephen J Qualman; Philip P Breitfeld
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

3.  PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.

Authors:  Edoardo Missiaglia; Dan Williamson; Julia Chisholm; Pratyaksha Wirapati; Gaëlle Pierron; Fabien Petel; Jean-Paul Concordet; Khin Thway; Odile Oberlin; Kathy Pritchard-Jones; Olivier Delattre; Mauro Delorenzi; Janet Shipley
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

4.  Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group.

Authors:  Elai Davicioni; James R Anderson; Jonathan D Buckley; William H Meyer; Timothy J Triche
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

Review 5.  The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker.

Authors:  Abby R Rosenberg; Stephen X Skapek; Douglas S Hawkins
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-07       Impact factor: 4.254
  5 in total
  1 in total

Review 1.  Current and Future Treatment Strategies for Rhabdomyosarcoma.

Authors:  Celine Chen; Heathcliff Dorado Garcia; Monika Scheer; Anton G Henssen
Journal:  Front Oncol       Date:  2019-12-20       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.